Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study
Year: 2016
Type: article
Study design: Observational Study
Abstract: Intravascular hemolysis in Paroxysmal nocturnal hemoglobinuria (PNH) can effectively be controlled with eculizumab, a humanized monoclonal antibody that binds complement protein C5. We report here a retrospective comparison study between 123 patients treated with eculizumab in the recent period (>2005) and 191 historical controls (from the French registry). Overall survival (OS) at 6 years was 92% (95%CI, 87 to 98) in the eculizumab cohort versus 80% (95%CI 70 to 91) in historical controls diagnosed after 1985 (HR 0.38 [0.15 to 0.94], P = 0.037). There were significantly fewer thrombotic events (TEs) in the group of patients treated with eculizumab (4% [1-10]) as compared to the historical cohort (27% [20-34]). However, we found that TEs may still occur after the initiation of eculizumab treatment and that previous TEs still have a negative impact on survival. Evolutions to myelodysplastic syndrome or acute leukemia were similar in both cohorts. There was less evolution to aplastic anemia in the treatment group. In multivariate analysis, absence of a previous TE and treatment with eculizumab were associated with a better OS. Treatment with eculizumab improves overall survival in classic PNH patients without increasing the risk of clonal evolution.
Source: American Journal of Hematology
DOI: 10.1002/ajh.24278
Authors: Michael Loschi, Raphael Porcher, Fiorenza Barraco, Louis Terriou, Mohamad Mohty, Sophie de Guibert, Beatrice Mahe, Richard Lemal, Pierre‐Yves Dumas, Gabriel Etienne, Fabrice Jardin, Bruno Royer, Dominique Bordessoule, Pierre Simon Rohrlich, Luc Mathieu Fornecker, Celia Salanoubat, Sebastien Maury, Jean‐Yves Cahn, Laure Vincent, Thomas Sene, Sophie Rigaudeau, Stephanie Nguyen, Anne‐Claire Lepretre, Jean‐Yves Mary, Bernadette Corront, Gerard Socie, Regis Peffault de Latour
Institutions: Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Centre Henri Becquerel, Inserm, Equipe de Recherche en Epidémiologie Nutritionnelle, Centre de Recherche Épidémiologie et Statistique, Université Paris Descartes, Hôpital Lyon Sud, Hôpital Claude Huriez, Hôpital Saint-Antoine, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Nantes, Nantes Université, Centre Hospitalier Universitaire de Clermont-Ferrand, Melun Hospital, Centre Hospitalier Universitaire Amiens-Picardie, Centre Hospitalier Universitaire de Limoges, Hôpital Universitaire Dupuytren, Centre Hospitalier Universitaire de Nice, Hôpitaux Universitaires de Strasbourg, Hôpital d'Hautepierre, Centre Hospitalier Sud Francilien, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, Centre Hospitalier Universitaire de Grenoble, Centre Hospitalier Universitaire de Montpellier, Hôpital Foch, Pitié-Salpêtrière Hospital, Établissement Français du Sang, Sorbonne Paris Cité, Centre Hospitalier Annecy Genevois
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W2209557348
